

Dedicated Expertise in Your Fight Against Blood Cancers

Full-Service Oncology CRO

Novella Clinical is a global, full-service clinical research organization (CRO) serving oncology sponsors as a trusted outsourcing partner for since 1998. We specialize in working with small to mid-sized biopharma companies, and work to address the unique complexities of clinical trials in hematologic malignancies. Novella offers global experience, hematology/oncology experienced staff, flexible and attentive solutions, and a robust infrastructure to support our customers from Phase I through approval.

Comprised of more than **700** oncology clinical trial specialists across all functional areas.

Hematology/Oncology Experience

Oncology is Novella's largest area of focus, having performed more than 450 oncology programs to date. Our dedicated Oncology Division is comprised of more than 700 oncology clinical trial specialists across all functional areas.

But within oncology, we recognize hematologic malignancies are distinct from solid tumors, and have built specific hematology/oncology teams and processes to support hematologic studies. Our specialists understand the clinical implications of blood-based cancers, the diverse pathologies, complex assessments, sick patient population, and lab-based endpoints inherent in hematological trials. We are proud that one-third of our oncology portfolio focuses specifically in hematology/oncology.

- Novella's trial portfolio includes 130+ hematology/oncology studies
 - AML, CML, CLL, DLBCL, NHL, MDS, MM and many rare indications
- Board-certified hematologists/oncologists on staff
- Currently working with cutting-edge immunotherapies (CAR-T) and targeted kinase inhibitors
- Predictive analytics to speed recruitment and drive enrollment


Hematology Oncology Drug Trial Experience

Novella has supported trials in general and rare hematologic malignancies, almost all being Phase I studies, as well as a number of trials in various leukemias, lymphomas and other indications.

Tumor Type	I/II	II	IIb/III	IV/EAP
General/Rare Hematologic Malignancies	17	4	2	0
Leukemia (ALL, AML, CLL, CML)	24	12	17	0
Lymphoma (ALCL, CTCL, NHL, PTCL, MCL)	16	9	6	0
Multiple Myeloma (MM)	8	5	2	1
Myelodysplastic Syndrome (MDS)	8	6	3	2

Biopharma-Centered Approach

With our corporate dedication to small and mid-sized biopharma companies, we provide the hands-on expertise of a specialty provider. Every trial is overseen by a senior-level executive who guides strategy and works closely with therapeutically aligned project managers and hematology/oncology specialists across functional disciplines. Novella offers transparent budgeting models and customized financial reporting to meet the specific needs of your organization.



Global Capabilities

Our experienced project teams, site and PI relationships and custom approach to serving biopharma companies enable us to support the complex nature of hematology trials from as early as a first-in-human trial. Novella has oncology experience in 50 countries, and through our parent company, QuintilesIMS, we offer direct access to unparalleled site and staff resources around the globe. This experience allows us to offer the global resources necessary to complete late phase, pivotal trials.

Visit our website for more

